ICD10 code of Pigmented villonodular synovitis and ICD9 code

Pigmented villonodular synovitis (PVNS), now more formally classified as tenosynovial giant cell tumor (TGCT), is coded as M67.2 in ICD-10 and 727.09 in ICD-9. These codes are essential for medical documentation and insurance processing, specifically identifying the localized or diffuse proliferative processes affecting the joint lining.

What is the clinical significance of the PVNS ICD-10 code?

The ICD-10 classification system uses the code M67.2 (Synovial hypertrophy, not elsewhere classified) to capture Pigmented villonodular synovitis. Because PVNS is a rare, tumor-like condition characterized by the proliferation of the synovium, clinicians must ensure the diagnosis is documented with precision. At DiseaseMaps.org, we have 31 community members who have navigated the diagnostic process for Pigmented villonodular synovitis; many report that clear coding is vital for securing coverage for expensive diagnostic imaging, such as contrast-enhanced MRI, which is the gold standard for visualizing the extent of the disease.

How does the ICD-9 code for Pigmented villonodular synovitis differ?

In the older ICD-9 framework, Pigmented villonodular synovitis was typically categorized under code 727.09 (Other synovitis and tenosynovitis). While ICD-9 is no longer used for current billing in the United States, it may still appear in older medical records. Understanding this transition is helpful for patients reviewing long-term clinical histories or requesting archival medical records when seeking second opinions from orthopedic oncologists.

What are the diagnostic features of Pigmented villonodular synovitis?

Pigmented villonodular synovitis is a rare proliferative disorder of the synovium. It can present in two forms: localized (often in the fingers or toes) or diffuse (typically affecting large joints like the knee). Key diagnostic features include:

• Joint swelling and pain: Persistent, often progressive, swelling in the affected joint.


• Mechanical symptoms: A sense of locking, catching, or limited range of motion due to the presence of mass-like tissue.


• Imaging findings: MRI often reveals "blooming" artifacts on gradient-recalled echo sequences, which are highly characteristic of the hemosiderin deposits found in Pigmented villonodular synovitis.


• Histopathology: A biopsy confirming the presence of multinucleated giant cells and hemosiderin-laden macrophages is required for a definitive diagnosis.

Is Pigmented villonodular synovitis considered a tumor?

Modern clinical literature, including the WHO classification of soft tissue tumors, now classifies Pigmented villonodular synovitis as a localized or diffuse tenosynovial giant cell tumor (TGCT). While these growths are typically benign, they are locally aggressive. They can cause significant bone erosion and joint destruction if left untreated. Because of this, the condition requires a specialized approach involving orthopedic oncology teams rather than standard orthopedic care.

Next steps for patients

• Consult an orthopedic oncologist who specializes in soft tissue tumors to discuss the most effective management strategies.


• Request a referral for a contrast-enhanced MRI if you have persistent joint effusion that does not resolve with conservative treatment.


• Join the Pigmented villonodular synovitis community at DiseaseMaps.org to connect with other patients who understand the diagnostic journey.


• Discuss the role of emerging systemic therapies, such as CSF1R inhibitors, with your specialist if surgery is not a viable option.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always consult with a qualified healthcare provider regarding your specific condition.

References

• Orphanet: Tenosynovial giant cell tumor (ORPHA:85458).


• NIH Genetic and Rare Diseases (GARD) Information Center: Pigmented villonodular synovitis (TGCT).


• World Health Organization (WHO) Classification of Tumours: Soft Tissue and Bone.


• The Sarcoma Foundation of America: Resources on Tenosynovial Giant Cell Tumor (TGCT).